We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSUMM.L Share News (SUMM)

  • There is currently no data for SUMM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sector movers: AstraZeneca, Shire lift pharma stocks on upbeat guidance

Tue, 14th Jan 2014 15:22

Decent gains from AstraZeneca and Shire gave the pharmaceuticals sector a boost on Tuesday as both firms gave confident outlooks.At the JP Morgan Healthcare Conference in San Francisco, AstraZeneca Chief Executive Pascal Soriot said he expects the company to return to growth sooner than analysts currently predict. He said that new incoming drugs from the company's portfolio as well as the buy-out of Bristol-Myers Squibb from their diabetes alliance should help halt a decline in sales. Sales have been under pressure over the last year due to a number of patent expiries and competition from generic versions of its drugs."AstraZeneca now expects 2017 revenues to be broadly in line with 2013 revenues," he said.The share price was 2.5% higher at around 3,755p by 15:50 on Tuesday.Toby Morris, Senior Sales Trader at CMC Markets, said: "The update comes ahead of a 2013 number release on Feb 6th, with a strong pipeline versus 12 months ago providing a boost in optimism and sending the stock higher."Shire, meanwhile, raised its earnings guidance for 2013 to the upper end of previous expectations, pushing the stock up 2.4% to 2,981p.Shire shares spiked immediately higher this afternoon as the Dublin-headquartered company put out a short statement from Chief Executive Flemming Ornskov that confirmed a strong finish to the year.Ornskov, who had been addressing investors at the same conference in San Francisco as AstraZeneca's Soriot, also added that he remained confident the company would deliver earnings for 2014 in line with the November 2013 consensus forecast (excluding ViroPharma).Others in the sector including Summit Corporation, Futura Medical and Skyepharma were making decent gains today.Vectura was also higher after the respiratory development company confirmed that its partner Sandoz has received Swedish marketing approval for their inhaler product AirFluSal Forspiro. Top performing sectors so far todayTechnology Hardware & Equipment 1,176.48 +1.16%Pharmaceuticals & Biotechnology 11,859.30 +0.85%Industrial Transportation 3,342.59 +0.78%Media 6,494.69 +0.73%Household Goods & Home Construction 11,269.09 +0.71%Bottom performing sectors so far todayElectronic & Electrical Equipment 4,505.01 -1.25%Industrial Metals & Mining 1,291.41 -1.24%Financial Services 7,863.20 -1.08%Oil & Gas Producers 8,257.45 -1.01%Forestry & Paper 10,922.16 -0.98%BC
More News
24 Feb 2020 10:52

Summit Therapeutics Delists In London As Focus Shifts To US

Summit Therapeutics Delists In London As Focus Shifts To US

Read more
24 Jan 2020 12:49

Summit Therapeutics Chief Operating & Medical Officer Roblin Resigns

Summit Therapeutics Chief Operating & Medical Officer Roblin Resigns

Read more
23 Jan 2020 16:47

Summit Gets More Funding For C. Difficile Infection Treatment

Summit Gets More Funding For C. Difficile Infection Treatment

Read more
24 Dec 2019 10:27

Summit Therapeutics Shuffles Board After Raising USD50 Million

Summit Therapeutics Shuffles Board After Raising USD50 Million

Read more
24 Dec 2019 09:09

Summit Therapeutics raises $40m, completes board restructuring

(Sharecast News) - Antibiotic innovation company Summit Therapeutics raised $50.0m on Tuesday by way of a subscription and placing of new ordinary shares and warrants.

Read more
17 Dec 2019 13:20

Summit Therapeutics Reports Decrease In Revenue In Third Quarter

Summit Therapeutics Reports Decrease In Revenue In Third Quarter

Read more
6 Dec 2019 13:34

Summit Therapeutics Plans Wholesale Changes As It Raises Cash

Summit Therapeutics Plans Wholesale Changes As It Raises Cash

Read more
6 Dec 2019 08:56

Summit Therapeutics raising $50m, plans to delist from AIM

(Sharecast News) - Antibiotic innovation company Summit Therapeutics announced a proposed fundraising of about $50m through a subscription and placing of new ordinary shares and warrants to existing investors on Friday, which would be subject to certain shareholder approvals being obtained and certain customary closing conditions being satisfied.

Read more
11 Oct 2019 12:53

Summit Therapeutics Sinks To Interim Loss On Ezutromid Discontinuation

Summit Therapeutics Sinks To Interim Loss On Ezutromid Discontinuation

Read more
7 Oct 2019 13:23

Summit Therapeutics Posts Explanation For Ridinilazole Trial In C Diff

Summit Therapeutics Posts Explanation For Ridinilazole Trial In C Diff

Read more
3 Oct 2019 14:23

Summit Therapeutics Reports Positive Ridinilazole Trial Results

Summit Therapeutics Reports Positive Ridinilazole Trial Results

Read more
17 Jul 2019 13:48

Summit Therapeutics New Antibiotic Shows Potential Against Gonorrhoea

(Alliance News) - Summit Therapeutics PLC on Wednesday highlighted the potential of its preclinical new class antibiotic, SMT-571, to treat gonorrhoea, at the STI & HIV World Congress in said

Read more
12 Jun 2019 13:54

Summit Therapeutics Narrows First Quarter Loss As Expenses Drop

(Alliance News) - Summit Therapeutics on Wednesday said its loss narrowed in its financial first quarter due to an increase in other operating income and a reduction in operating which develops a

Read more
15 Apr 2019 11:26

Summit Therapeutics DDS-04 Series Antibiotic Cures Infection In Study

LONDON (Alliance News) - Summit Therapeutics PLC on Monday presented proof of concept data for its DDS-04 series of antibiotics targeting Enterobacteriaceae, a family of bacteria that cause severe

Read more
15 Apr 2019 10:16

Summit Therapeutics upbeat on latest DDS-04 data

(Sharecast News) - Antibiotic innovation firm Summit Therapeutics reported on in vivo proof-of-concept data for the DDS-04 series of new mechanism antibiotics targeting enterobacteriaceae on Monday, having presented them at the 29th European Congress of Clinical Microbiology and Infectious Diseases in Amsterdam.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.